European Medicines Agency (EMA)/ Medicines and Healthcare Product Regulation Authority (MHRA) Meeting on Sodium Valproate Article 31 Referral.

Activity: Internal positions, career professional development and otherOtherResearch


I was invited to this meeting to present our research data pertaining to the risks associated with prenatal exposure to valproate. This was part of a series of meetings for the Article 31 Referral regarding valproate use in pregnancy. Following the completion of this review the European Medicines Agency announced measures to restrict the prescribing of valproate in women and girls of childbearing age.
Period26 Feb 2014


  • Teratology
  • Regulators
  • Epilepsy
  • Pregnancy
  • pharmacovigilance
  • Neuropsychology
  • Neurodevelopment